Essential information

Ongoing leadership
Sophisticated talent
Entrepreneural Enviroment
A Latin American hub

Sinovac

Tags:

Sinovac: Chile becomes a hub for vaccine production

Sinovac Biotech is a Chinese company dedicated to the research, development, production and commercialization of vaccines against infectious diseases such as hepatitis A and B, seasonal influenza, pandemic influenza H5N1 and H1N1, and mumps. Furthermore, their COVID-19 vaccine, CoronaVac, has been approved for emergency or conditional commercial use in over 40 countries or regions worldwide.

The laboratory has four production centres located in Beijing’s Haidian and Changping districts, the city of Dalian in Liaoning Province, and the city of Tangshan in Hebei Province. The company has actively expanded its operations outside of China and established administrative and business teams abroad, committed to supplying products and services to meet the global need to prevent and control diseases.

Today, the company has representatives in the USA, India, the UK, Spain, Italy and Chile.

In August 2021, backed by the support of InvestChile, Sinovac announced the construction of their first vaccine production plant in Chile, in the municipality of Quilicura. In the initial phase, the plant will carry out the filling and finishing of the vaccines, a process which will turn Chile into the hub of Sinovac operations in Latin America. “Through vaccine production in Chile, we can supply vaccines to the whole world. At the same time, we can create many new jobs,” explained Qiang Gao, CEO of the Sinovac laboratory. The initiative, which is also supported by the Universidad Católica and the Science, Technology, Knowledge and Innovation Ministry, will help strengthen the field of pharmaceutical research and development in Chile.

The plant will produce up to 50 million vaccines against such diseases as COVID-19, hepatitis and influenza. Vaccines against polio and chicken pox will also be produced at a later stage. Sinovac has committed to spending USD $100 million on the construction of the plant.

Tags:
Back

Details

Company: Sinovac
Investment Country: China
OTHER SUCCESS STORIES
China RailwayBetterflyGold FieldsMicrosoft